| The Renal Cell Carcinoma Drug Market Will Experience Robust 3.7 Percent Annual ... - MarketWatch (press release) |
|
|
MarketWatch (press release) BURLINGTON, Mass., Dec 08, 2011 (BUSINESS WIRE) -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the renal cell carcinoma drug market will experience robust 3.7 percent |